Positive News SentimentPositive NewsNASDAQ:QTTB Q32 Bio (QTTB) Stock Price, News & Analysis → Trump’s arrest is phase one (From Porter & Company) (Ad) Free QTTB Stock Alerts $25.50 -1.85 (-6.76%) (As of 05/31/2024 ET) Add Compare Share Share Today's Range$25.50▼$26.9850-Day Range$17.04▼$31.0052-Week Range$8.24▼$32.88Volume66,742 shsAverage Volume36,156 shsMarket Capitalization$304.47 millionP/E RatioN/ADividend YieldN/APrice Target$49.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsTrends Get Q32 Bio alerts: Email Address Q32 Bio MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside94.8% Upside$49.67 Price TargetShort InterestN/ADividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$6,488 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($10.74) to ($4.59) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.24 out of 5 starsMedical Sector587th out of 928 stocksPharmaceutical Preparations Industry276th out of 437 stocks 3.6 Analyst's Opinion Consensus RatingQ32 Bio has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageQ32 Bio has only been the subject of 4 research reports in the past 90 days.Read more about Q32 Bio's stock forecast and price target. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for QTTB. Previous Next 0.0 Dividend Strength Dividend YieldQ32 Bio does not currently pay a dividend.Dividend GrowthQ32 Bio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for QTTB. Previous Next 3.2 News and Social Media Coverage News SentimentQ32 Bio has a news sentiment score of 1.73. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.78 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Q32 Bio this week, compared to 2 articles on an average week.Search Interest5 people have searched for QTTB on MarketBeat in the last 30 days. This is an increase of 150% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Q32 Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $6,488.00 in company stock.Percentage Held by Insiders16.10% of the stock of Q32 Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.32% of the stock of Q32 Bio is held by institutions.Read more about Q32 Bio's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Q32 Bio are expected to grow in the coming year, from ($10.74) to ($4.59) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Q32 Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Q32 Bio is -0.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioQ32 Bio has a P/B Ratio of 6.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Q32 Bio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceWarren Buffett, Jeff Bezos, Michael Bloomberg, & 48 Members of Congress Are Buying ONE Sector…Why are Warren Buffett, Jeff Bezos, Michael Bloomberg, “The Walmart Family”, Bill Gates, and 48 members of Congress shifting their stocks in a frenzy? And why are they all piling into ONE unique corner of the market…Click here for the details About Q32 Bio Stock (NASDAQ:QTTB)Q32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States. Its lead product candidate is ADX-097, a humanized anti-C3d monoclonal antibody fusion protein to restore complement regulation, which has completed Phase I clinical trial for the treatment of renal and other complement-mediated diseases of high unmet need, including lupus nephritis, immunoglobulin A nephropathy, complement component 3 glomerulopathy, and anti-neutrophil cytoplasmic antibody-associated vasculitis. The company is also developing Bempikibart (ADX-914), a fully human antiinterleukin-7 receptor alpha antagonist monoclonal antibody designed to re-regulate adaptive immune function by blocking signaling mediated by interleukin-7 and thymic stromal lymphopoietin that is Phase II clinical trial for the treatment of atopic dermatitis and alopecia areata. Q32 Bio Inc. was formerly known as AdMIRx Inc. and changed its name to Q32 Bio Inc. in April 2020. The company was founded in 2017 and is based in Waltham, Massachusetts.Read More QTTB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart QTTB Stock News HeadlinesMay 23, 2024 | americanbankingnews.comResearch Analysts Offer Predictions for Q32 Bio Inc.'s Q2 2024 Earnings (NASDAQ:QTTB)May 23, 2024 | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Lifted to Strong-Buy at Leerink PartnrsMay 22, 2024 | americanbankingnews.comQ32 Bio (NASDAQ:QTTB) Now Covered by SVB LeerinkMay 22, 2024 | msn.comLeerink Partners Initiates Coverage of Q32 Bio (QTTB) with Outperform RecommendationMay 21, 2024 | markets.businessinsider.comBuy Rating Justified by Q32 Bio’s Promising Pipeline and Market PotentialMay 9, 2024 | investorplace.comQTTB Stock Earnings: Q32 Bio Misses EPS for Q1 2024May 9, 2024 | prnewswire.comQ32 Bio Reports First Quarter 2024 Financial Results and Provides Corporate UpdateApril 12, 2024 | msn.comVeru, Theravance Biopharma, Adial Pharmaceuticals among healthcare moversApril 12, 2024 | investing.comQ32 Bio stock target upgraded on strong drug potentialApril 8, 2024 | uk.investing.comQ32 Bio Inc (QTTB)April 5, 2024 | uk.investing.comQ32 Bio names Lee Kalowski as President and CFOApril 3, 2024 | finance.yahoo.comQ32 Bio Appoints Lee Kalowski as President & Chief Financial OfficerSee More Headlines Receive QTTB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Q32 Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today6/01/2024Next Earnings (Estimated)8/12/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:QTTB Previous SymbolNASDAQ:QTTB CUSIPN/A CIK1661998 Webwww.homologymedicines.com Phone781-301-7277FaxN/AEmployees37Year FoundedN/APrice Target and Rating Average Stock Price Target$49.67 High Stock Price Target$54.00 Low Stock Price Target$45.00 Potential Upside/Downside+94.8%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($32.5890) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-112,960,000.00 Net MarginsN/A Pretax Margin-22,326.84% Return on Equity-117.63% Return on Assets-70.92% Debt Debt-to-Equity Ratio0.19 Current Ratio4.19 Quick Ratio4.19 Sales & Book Value Annual Sales$1.16 million Price / Sales262.47 Cash FlowN/A Price / Cash FlowN/A Book Value$4.08 per share Price / Book6.25Miscellaneous Outstanding Shares11,940,000Free Float10,019,000Market Cap$304.47 million OptionableN/A Beta-0.26 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesMs. Jodie Pope Morrison (Age 48)CEO & Director Comp: $852.63kDr. Shelia M. Violette Ph.D. (Age 63)Co-founder, Chief Scientific Officer & President of Research Comp: $619.93kDr. Jason A. Campagna M.D. (Age 57)Ph.D., Chief Medical Officer Comp: $680.93kMr. Lee H. Kalowski M.B.A. (Age 43)CFO, President & Treasurer Dr. Saul Fink Ph.D.Chief Technology OfficerMr. David Appugliese J.D.Senior VP & Head of PeopleMs. Maria Marzilli M.P.H.Executive Vice President of Corporate Strategy & Program OperationsMs. Kathryn E. Golden M.B.A.Head of Chemistry, Manufacturing & ControlsMore ExecutivesKey CompetitorsKiniksa PharmaceuticalsNASDAQ:KNSAANI PharmaceuticalsNASDAQ:ANIPSpyre TherapeuticsNASDAQ:SYREAkero TherapeuticsNASDAQ:AKROMannKindNASDAQ:MNKDView All CompetitorsInsiders & InstitutionsIkarian Capital LLCBought 22,335 shares on 5/17/2024Ownership: 0.685%ARCH Venture Management LLCBought 320,482 shares on 5/15/2024Ownership: 9.831%Affinity Asset Advisors LLCBought 27,777 shares on 5/15/2024Ownership: 0.852%Platinum Investment Management Ltd.Bought 109,964 shares on 5/14/2024Ownership: 3.373%Acadian Asset Management LLCBought 3,695 shares on 5/10/2024Ownership: 0.113%View All Insider TransactionsView All Institutional Transactions QTTB Stock Analysis - Frequently Asked Questions Should I buy or sell Q32 Bio stock right now? 4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Q32 Bio in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" QTTB shares. View QTTB analyst ratings or view top-rated stocks. What is Q32 Bio's stock price target for 2024? 4 Wall Street analysts have issued 12 month target prices for Q32 Bio's shares. Their QTTB share price targets range from $45.00 to $54.00. On average, they anticipate the company's stock price to reach $49.67 in the next year. This suggests a possible upside of 94.8% from the stock's current price. View analysts price targets for QTTB or view top-rated stocks among Wall Street analysts. How have QTTB shares performed in 2024? Q32 Bio's stock was trading at $17.04 at the start of the year. Since then, QTTB stock has increased by 49.6% and is now trading at $25.50. View the best growth stocks for 2024 here. When is Q32 Bio's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, August 12th 2024. View our QTTB earnings forecast. How were Q32 Bio's earnings last quarter? Q32 Bio Inc. (NASDAQ:QTTB) posted its earnings results on Thursday, May, 9th. The company reported ($13.15) EPS for the quarter, missing the consensus estimate of ($1.42) by $11.73. Who are Q32 Bio's major shareholders? Q32 Bio's stock is owned by a number of retail and institutional investors. Top institutional investors include Atlas Venture Life Science Advisors LLC (64.25%), Carlyle Group Inc. (33.83%), Vivo Capital LLC (11.37%), ARCH Venture Management LLC (9.83%), Platinum Investment Management Ltd. (3.37%) and Vanguard Group Inc. (3.31%). View institutional ownership trends. How do I buy shares of Q32 Bio? Shares of QTTB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:QTTB) was last updated on 6/1/2024 by MarketBeat.com Staff From Our PartnersDems have chosen Biden replacement?Paradigm PressTrump’s Gift Could Unleash $51 Billion in New WealthWealthpin ProShocking: One AI startup's revenue could surge 4,735%Manward PressMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia has Apple and Microsoft within striking rangeWeiss RatingsDon’t buy a single NVIDIA share before you see this...Behind the MarketsExposed: 10 CENT Crypto to Explode May 20th?True Market InsidersHe Is Giving Away BitcoinCrypto Swap Profits Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Q32 Bio Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
